BUPROPION Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Bupropion, and when can generic versions of Bupropion launch?
Bupropion is a drug marketed by Accord Hlthcare, Actavis Labs Fl Inc, Anbison Lab, Annora Pharma, Aurobindo Pharma Usa, Chartwell Rx, Epic Pharma Llc, Granules, Graviti Pharms, Impax Labs, Invagen Pharms, Ipca Labs Ltd, Jubilant Generics, Lupin, Ph Health, Prinston Inc, Rising, Sandoz, Sciegen Pharms, Sinotherapeutics Inc, Sun Pharm, Torrent, Twi Pharms, Watson Labs Inc, Wockhardt Ltd, Yichang Humanwell, Zhejiang Jutai Pharm, Zydus Pharms, Alembic, Apotex, Cadila Pharms Ltd, Heritage Pharma, Invatech, Micro Labs, and Senores Pharms. and is included in sixty-two NDAs.
The generic ingredient in BUPROPION is bupropion hydrochloride. There are thirty-eight drug master file entries for this compound. Seventy-four suppliers are listed for this compound. Additional details are available on the bupropion hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bupropion
A generic version of BUPROPION was approved as bupropion hydrochloride by SENORES PHARMS on February 7th, 2000.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BUPROPION?
- What are the global sales for BUPROPION?
- What is Average Wholesale Price for BUPROPION?
Summary for BUPROPION
| US Patents: | 0 |
| Applicants: | 35 |
| NDAs: | 62 |
| Drug Prices: | Drug price information for BUPROPION |
| Drug Sales Revenues: | Drug sales revenues for BUPROPION |
| DailyMed Link: | BUPROPION at DailyMed |
US Patents and Regulatory Information for BUPROPION
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sciegen Pharms | BUPROPION HYDROCHLORIDE | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 207479-002 | Apr 12, 2017 | AB3 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Yichang Humanwell | BUPROPION HYDROCHLORIDE | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 220529-002 | May 4, 2026 | AB1 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Invagen Pharms | BUPROPION HYDROCHLORIDE | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 206674-003 | Feb 9, 2016 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Impax Labs | BUPROPION HYDROCHLORIDE | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 075913-001 | Jan 28, 2004 | AB1 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Watson Labs Inc | BUPROPION HYDROCHLORIDE | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 077455-001 | Jul 19, 2010 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Aurobindo Pharma Usa | BUPROPION HYDROCHLORIDE | bupropion hydrochloride | TABLET;ORAL | 075491-002 | Apr 17, 2000 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
